Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand

Laboratory-engineered immune cells called CAR T cells provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo.

Epstein–Barr virus infection generates a neuroinvasive B cell subset, which recruits activated T cells to the central nervous system, promoting multiple sclerosis.

Researchers identified anoctamin-2 (ANO2) as a frequent autoimmune target in multiple sclerosis, with T cell responses against ANO2 occurring in over half of patients. These ANO2-specific T cells shar...

Immune cells lose their cancer-fighting prowess after taking tumours’ organelles on board.

In a Chinese study, donor CAR-T cells sent autoimmune diseases into remission. There’s hope that the therapy is scalable.

ACLY-deficient CAR T cells targeting the tumor-associated antigen disialoganglioside GD2 (GD2 CAR T cells) also resisted acquiring TEX-like properties, exhibiting reduced CD39 expression when co-cultu...

Classically, B and T cells are differentiated by their mutually exclusive expression of surface markers such as CD3 and CD20, but it is now establi...

Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells to promote pathogenic antinuclear T and B cell responses in lupus.

Scientists have developed a 'molecular GPS' to guide immune cells into the brain and kill tumors without harming healthy tissue.

In a small trial of patients with severe systemic lupus erythematosus and nephritis, treatment with allogeneic T cells with a CD19 chimeric antigen receptor inserted into the T cell receptor locus and...

Experts praise groundbreaking results from therapy using genetically modified Car T-cells Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to “exciting” and “groundbreaking” results from a world-first clinical trial. Car T-cell therapy is a new form of immunotherapy where a patient’s own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease. Continue reading...

Resting T cells are difficult to manipulate, and are a reservoir for latent HIV. Here, the authors develop a lipid nanoparticle formulation with the ability to transfect resting primary human T cells,...